Community participation gaps look less like a question of patient willingness and more like a financing and infrastructure problem that no single bill has yet solved.
|Articles|May 24, 2023
OCT East 2023: Achieving Global DEIA in Clinical Trials
Author(s)Andy Studna, Senior Editor
Harsha K. Rajasimha, PhD, founder and executive chairman, IndoUSrare, provides the OCT audience insights into better achieving DEIA clinical trials.
Advertisement
In a presentation at Outsourcing in Clinical Trials East Coast 2023, Harsha K. Rajasimha, PhD, founder and executive chairman, IndoUSrare, and former guest of the Applied Clinical Trials
To begin, Rajasimha pointed out that the access portion has “gone missing.” Of the major considerations typically taken into account in clinical trials: patient recruitment and retention, managing protocol complexity and amendments, vendor management, and manual repetitive tasks and errors; all of which are overshadowed by cost, diversity is often left out.
What are the largest barriers to achieving DEIA in clinical trials? Geographic location is a major pain point, which is nothing new to industry. There often isn’t alignment on complex cultural barriers such as language, religious beliefs, and dietary restrictions. A lack of data for all diversity parameters, especially in rare diseases, as well as mistrust among diverse populations are also major barriers.
Rajasimha addressed that one of, if not the largest issue within mistrust among diverse populations is that they are less frequently asked to participate in trials.
How can these paint points be addressed to work towards achieving DEIA in trials? It starts with regulatory policies, mandates, and guidelines. There also must be a commitment among all stakeholders with a shared goal. This includes global thinking and cross-border collaboration as well as more inclusive digital and data platforms. An overarching solution is implementing next generation training and education programs for cultural competency for clinical trial stakeholders.
While the COVID-19 pandemic disrupted many aspects of the clinical trials industry, it has provided the opportunity for stakeholders to reflect on pain points such as diversity. Rajasimha concluded by noting that industry has never been so open to new ideas and technology. The time to make clinical trials more accessible is now.
Advertisement
Related to this article
In this video interview, Kent Thoelke, CEO of Paradigm Health, calls for safe harbor protections, CMS reimbursement safeguards, and funding mechanisms modeled on EHR meaningful use to help community and rural institutions participate in research on par with academic centers.
In this video interview, Kent Thoelke, CEO of Paradigm Health, explains why patients in community and rural settings too often lack access to clinical research as a care option, and how closing that gap could improve outcomes and lower long-term costs.
In this video interview, Kent Thoelke, CEO of Paradigm Health, outlines why anti-kickback guidance and modern EHR-integrated trial matching technology must work in tandem to reach representative patient populations at the community level.
In this video interview, Kent Thoelke, CEO of Paradigm Health, describes how manual eligibility screening and swivel-chair data entry force community sites to trade billable patient care for research, and why that burden is so hard to absorb.
In this video interview, Kent Thoelke, CEO of Paradigm Health, explains why patient cost barriers and site infrastructure challenges must be solved together to close the participation gap in community and rural clinical trials.
Mistral and OpenAI produced identical overall eligibility labels across 200 synthetic patient-study assessments, with criterion-level disagreements concentrated in inclusion criteria where models switch between “Uncertain” and “Not included” when records lack sufficient evidence, so model choice should be driven by deployment architecture, control, and cost rather than assumed interchangeability.
In Episode 4 of The Human Side of Clinical Trials, host Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., speaks with Jason Riis, PhD, CEO and chief behavioral scientist at Behavioralize, about how capturing friction closer to the moment it happens can reveal unclear instructions, technology friction, and workarounds that retrospective surveys and debriefs tend to miss.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Embedding AI Across the Clinical Operating Model: Q&A with Rajneesh Patil, Syneos Health
2
From Signal to Action: Why Faster Trial Data Isn’t Producing Faster Decisions
3
From Complexity to Endpoint Meaningfulness: Addressing Key Neuroscience Trial Challenges with eCOA
4
Beyond the Modernization Act: What It Takes to Make Community Research Infrastructure Permanent
5